Agitation clinical trials at University of California Health
2 research studies open to eligible people
Showing trials for
Masupirdine for the Treatment of Agitation in Dementia of the Alzheimer's Type
open to eligible people ages 50-90
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitation in participants with dementia of the Alzheimer's type.
at UCLA
BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
open to eligible people ages 55-90
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.
at UCSD
Last updated: